Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ABT · NYSE · Health Care Equipment
Abbott Laboratories (ABT) · oqro.io/stocks/ABT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$104.48−0.23 (−0.22%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
No open-market purchase by an insider of Abbott Laboratories was filed in the last 90 days. The latest on record was on Jun 18, 2026.
Since 2006, Abbott Laboratories insiders reported 377 open-market purchases and 3,222 sales on Forms 4 and 5, with purchases in 13 different years, most recently 2026.
In the last 90 days, 3 insiders of Abbott Laboratories (ABT) reported 4 open-market sales worth $46.6M in total on SEC Form 4. The largest seller by value was Robert B Ford, with $46.2M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 28 trades in Abbott Laboratories (ABT) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Thomas H. Kean Jr. (NJ07), Rep. Pete Sessions (TX17), Rep. Gilbert Ray Cisneros Jr. (CA31) and 10 other members.
Abbott Laboratories's next results are expected on Jan 20, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−19.6% (−$25.52) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $130.00 on Nov 18, 2025 to $104.48 on Nov 18, 2026 (−19.6%). Disclosed in this range: 18 insider trades, 0 pre-arranged insider sales, 24 Congress trades, and 247 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in North Chicago, Illinois.
Last 12 months
−19.6%
Market value
$181B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 19.1M shares sold short (1.1% of shares outstanding), +9.6% vs the previous count, 1.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Abbott Laboratories: 1 fund cut or exited a position in the latest available 13F filings and 2 members of Congress disclosed sales. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue
$13B
+14.5% vs the same quarter a year earlier
Free cash flow, last 12 months
$6.76B
This quarter $1.22B, a year earlier $2.29B
Net debt
$27.1B
Debt $31.2B, cash $4.05B, at Sep 30, 2026
Net income, last 12 months
$4.7B
Operating profit covers interest 6.7x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 21, 2026.
Revenue, fiscal 2025
$44.3B
+5.7% vs the year before
Net income, fiscal 2025
$6.52B
As reported in the annual filing
Shares outstanding
1.73B
As of Sep 30, 2026
In fiscal 2025 the company spent $893M buying back its own shares and $4.12B on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Nov 5 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −8.0% · S&P 500 −0.4% · to Nov 18
Abbott Laboratories's EXECUTIVE VICE PRESIDENT sold $406K of Abbott Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Congress
Traded Sep 17 · disclosed 43 days laterSits on House Energy and Commerce
Since the trade +2.2% · S&P 500 −4.3% · to Nov 18
7 different filers disclosed ABT within 90 days.
Congress
Traded Oct 2 · disclosed 25 days laterSpouse
Since the trade +7.2% · S&P 500 −5.1% · to Nov 18
6 different filers disclosed ABT within 90 days.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Abbott Laboratories over the 12 months to Nov 18, 2026: 22 FDA records and 6 executive contributions.
Insiders of Abbott Laboratories reported 377 open-market purchases and 3,222 sales since 2006; purchases in 13 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $4.4M6×6 trades | $47.7M11×11 trades |
| 2025 | — | $79.2M15×15 trades |
| 2024 | — | $45.2M17×17 trades |
| 2023 | — | $21.8M29×29 trades |
| 2022 | — | $38.8M31×31 trades |
| 2021 | $250K1×1 trade | $131M51×51 trades |
| 2020 | — | $99M40×40 trades |
| 2019 | $397K6×6 trades | $181M265×265 trades |
| 2018 | $4.24M59×59 trades | $92M409×409 trades |
| 2017 | $555K2×2 trades | $76.6M229×229 trades |
| 2016 | $47.7M279×279 trades | $5.96M48×48 trades |
| 2015 | — | $29.5M121×121 trades |
| 2014 | $2K1×1 trade | $25.4M60×60 trades |
| 2013 | $342K8×8 trades | $14.5M72×72 trades |
| 2012 | — | $123M408×408 trades |
| 2011 | — | $88.2M523×523 trades |
| 2010 | $171K3×3 trades | $33.3M247×247 trades |
| 2009 | $194K2×2 trades | $76.4M264×264 trades |
| 2008 | $219K6×6 trades | $33.8M180×180 trades |
| 2007 | $568K2×2 trades | $67.6M166×166 trades |
| 2006 | $107K2×2 trades | $4.89M36×36 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 13, 2025, ABT is down 19.0% and the index fund is up 9.0%: 28 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ABT moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Foreign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
Notice · Foreign-Trade Zones Board
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
Proposed rule · Centers for Medicare & Medicaid Services
Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
25 certified in FY2026 Q3, vs 33 a year earlier. 25 positions in total, median offered wage $110K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 38.4% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 35.7%. FINRA daily files, to Nov 18, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
16 approvals or clearances and 10 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last results
Oct 21, 2026
Within the 30 days after it, until Nov 20, 2026
Next results, expected
Jan 20, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
100%
13 of 13 insider purchases since 2018 came within 30 days after a results announcement
From Abbott Laboratories's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Abbott Laboratories's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.